427 Park Street
Charlottesville, VA 22902
United States
434 297 1000
https://acumenpharm.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 51
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Daniel J. O'Connell M.B.A. | CEO & Director | 1,04M | S.O. | 1970 |
Mr. Matt Zuga | CFO & Chief Business Officer | 702,6k | S.O. | S.O. |
Mr. Derek M. Meisner Esq., J.D. | Chief Legal Officer & Corporate Secretary | 752,95k | S.O. | 1971 |
Dr. James Doherty Ph.D. | President & Chief Development Officer | S.O. | S.O. | 1968 |
Dr. Grant A. Krafft Ph.D. | Co-Founder | 42k | S.O. | S.O. |
Dr. Caleb E. Finch Ph.D. | Co-Founder | S.O. | S.O. | S.O. |
Dr. William L. Klein Ph.D. | Co-Founder | S.O. | S.O. | S.O. |
Mr. Russell Barton M.S. | Chief Operating Officer | 223,68k | S.O. | 1959 |
Ms. Kelly Carranza | Vice President, Finance & Accounting and Corporate Controller | S.O. | S.O. | S.O. |
Ms. Alex Braun M.B.A. | VP & Head of Investor Relations | S.O. | S.O. | S.O. |
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
L’ISS Governance QualityScore de Acumen Pharmaceuticals, Inc. en date du 1 mai 2024 est 8. Les scores principaux sont Audit : 9; Société : 6; Droits des actionnaires : 8; Compensation : 9.